Stockscreener 앱 받기
17.72
3.22%
0.46
전일 마감가:
$17.26
열려 있는:
$17.45
하루 거래량:
14,556
Relative Volume:
0.08
시가총액:
$1.19B
수익:
$-9,000
순이익/손실:
$-68.03M
주가수익비율:
-16.88
EPS:
-1.05
순현금흐름:
$-44.76M
1주 성능:
-10.66%
1개월 성능:
+13.18%
6개월 성능:
+4.61%
1년 성능:
+8.69%
1일 변동 폭
$17.36
$17.82
1주일 범위
$16.76
$20.00
52주 변동 폭
$13.77
$25.00
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
PLSE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
17.71 | 1.16B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
438.11 | 156.44B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
188.69 | 53.99B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
270.86 | 39.41B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
75.01 | 36.63B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
262.69 | 18.78B | 2.96B | 487.70M | 344.00M | 6.6758 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
Using data filters to optimize entry into Pulse Biosciences Inc.July 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com
Why hedge funds are buying Pulse Biosciences Inc. stockTreasury Yields & AI Powered Market Entry Ideas - newser.com
Is this a good reentry point in Pulse Biosciences Inc.July 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Using fundamentals and technicals on Pulse Biosciences Inc.Portfolio Performance Report & High Return Trade Opportunity Guides - newser.com
Sector ETF performance correlation with Pulse Biosciences Inc.2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Visualizing Pulse Biosciences Inc. stock with heatmapsBear Alert & Detailed Earnings Play Strategies - newser.com
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse - Yahoo Finance
Tick level data insight on Pulse Biosciences Inc. volatility2025 Buyback Activity & Daily Growth Stock Tips - newser.com
Will Pulse Biosciences Inc. stock beat EPS estimates2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Pulse Biosciences (PLSE): Assessing Valuation After Recent Share Price Swings - Yahoo Finance
Pulse Biosciences’ Npulse successful in epicardial PFA - BioWorld MedTech
Pulse Biosciences Reveals Positive First-in-Human PFA Data - Medical Product Outsourcing
Is Pulse Biosciences Inc. stock bottoming outJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
Pulse Biosciences announces presentation of late-breaking data from the nPulse cardiac surgical system - MarketScreener
Pulse Biosciences Announces Results from nPulse Cardiac Surgical System Study - TradingView
Pulse Biosciences reports positive results for cardiac ablation system By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - MarketScreener
Pulse Biosciences reports positive results for cardiac ablation system - Investing.com India
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Is now a turning point for Pulse Biosciences Inc.July 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Pulse Biosciences (NASDAQ:PLSE) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Heatmap analysis for Pulse Biosciences Inc. and competitorsJuly 2025 Trends & Long-Term Capital Growth Strategies - newser.com
Will Pulse Biosciences Inc. continue its uptrendMarket Activity Summary & Real-Time Sentiment Analysis - newser.com
What analysts say about Pulse Biosciences Inc 6L8 stockTrendline Breakouts & Outstanding Investment Portfolio - earlytimes.in
Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells 4,600 Shares of Stock - MarketBeat
Pulse Biosciences introduces nPulse Vybrance for nsPFA technology - Traders Union
Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Investing News Network
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Pulse Biosciences (PLSE) Is Up 11.1% After FDA Clears Cardiac Ablation StudyWhat's Changed - Sahm
Pulse Biosciences (PLSE): Evaluating Its Valuation After Recent Investor Interest - Sahm
Using Ichimoku Cloud for Pulse Biosciences Inc. technicals2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
What does recent volatility data suggest for Pulse Biosciences Inc.Buy Signal & Momentum Based Trading Signals - newser.com
Pulse Biosciences Expands Equity Incentive Plan - MSN
Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial - Insider Monkey
What drives Pulse Biosciences Inc 6L8 stock priceStock Buy Signals & Invest Now – Opportunity Window Closing - earlytimes.in
First Procedures Conducted in PRECISE Benign Thyroid Nodule Study - Medical Product Outsourcing
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
펄스 바이오 주식 (PLSE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
0.18%
1.17%
자본화:
|
볼륨(24시간):